Literature DB >> 26746812

Review: Clinical aspects of hereditary DNA Mismatch repair gene mutations.

Rolf H Sijmons1, Robert M W Hofstra2.   

Abstract

Inherited mutations of the DNA Mismatch repair genes MLH1, MSH2, MSH6 and PMS2 can result in two hereditary tumor syndromes: the adult-onset autosomal dominant Lynch syndrome, previously referred to as Hereditary Non-Polyposis Colorectal Cancer (HNPCC) and the childhood-onset autosomal recessive Constitutional Mismatch Repair Deficiency syndrome. Both conditions are important to recognize clinically as their identification has direct consequences for clinical management and allows targeted preventive actions in mutation carriers. Lynch syndrome is one of the more common adult-onset hereditary tumor syndromes, with thousands of patients reported to date. Its tumor spectrum is well established and includes colorectal cancer, endometrial cancer and a range of other cancer types. However, surveillance for cancers other than colorectal cancer is still of uncertain value. Prophylactic surgery, especially for the uterus and its adnexa is an option in female mutation carriers. Chemoprevention of colorectal cancer with aspirin is actively being investigated in this syndrome and shows promising results. In contrast, the Constitutional Mismatch Repair Deficiency syndrome is rare, features a wide spectrum of childhood onset cancers, many of which are brain tumors with high mortality rates. Future studies are very much needed to improve the care for patients with this severe disorder.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Constitutional Mismatch Repair Deficiency syndrome; DNA Mismatch repair; Lynch syndrome; MLH1; MSH2; MSH6; PMS2; clinic; review

Mesh:

Year:  2015        PMID: 26746812     DOI: 10.1016/j.dnarep.2015.11.018

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  22 in total

1.  Elucidating the clinical significance of two PMS2 missense variants coexisting in a family fulfilling hereditary cancer criteria.

Authors:  Maribel González-Acosta; Jesús Del Valle; Matilde Navarro; Bryony A Thompson; Sílvia Iglesias; Xavier Sanjuan; María José Paúles; Natàlia Padilla; Anna Fernández; Raquel Cuesta; Àlex Teulé; Guido Plotz; Juan Cadiñanos; Xavier de la Cruz; Francesc Balaguer; Conxi Lázaro; Marta Pineda; Gabriel Capellá
Journal:  Fam Cancer       Date:  2017-10       Impact factor: 2.375

2.  Low Levels of Microsatellite Instability at Simple Repeated Sequences Commonly Occur in Human Hepatocellular Carcinoma.

Authors:  Claire Goumard; Christele Desbois-Mouthon; Dominique Wendum; Claire Calmel; Fatiha Merabtene; Olivier Scatton; Françoise Praz
Journal:  Cancer Genomics Proteomics       Date:  2017 Sep-Oct       Impact factor: 4.069

Review 3.  Predispositions to Leukemia in Down Syndrome and Other Hereditary Disorders.

Authors:  Satoshi Saida
Journal:  Curr Treat Options Oncol       Date:  2017-07

4.  Reduced microRNA-188-3p expression contributes to apoptosis of spermatogenic cells in patients with azoospermia.

Authors:  Wen-Yan Song; Hui Meng; Xue-Gai Wang; Hai-Xia Jin; Gui-Dong Yao; Sen-Lin Shi; Liang Wu; Xiang-Yang Zhang; Ying-Pu Sun
Journal:  Cell Prolif       Date:  2016-11-21       Impact factor: 6.831

Review 5.  Translational Research in Familial Colorectal Cancer Syndromes.

Authors:  Molly M Ford
Journal:  Clin Colon Rectal Surg       Date:  2018-05-01

6.  Cancer Progress and Priorities: Uterine Cancer.

Authors:  Ashley S Felix; Louise A Brinton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-09       Impact factor: 4.254

7.  A genetic variant in telomerase reverse transcriptase (TERT) modifies cancer risk in Lynch syndrome patients harbouring pathogenic MSH2 variants.

Authors:  Mariann Unhjem Wiik; Tiffany-Jane Evans; Sami Belhadj; Katherine A Bolton; Dagmara Dymerska; Shantie Jagmohan-Changur; Gabriel Capellá; Grzegorz Kurzawski; Juul T Wijnen; Laura Valle; Hans F A Vasen; Jan Lubinski; Rodney J Scott; Bente A Talseth-Palmer
Journal:  Sci Rep       Date:  2021-05-31       Impact factor: 4.379

8.  Precancer Atlas to Drive Precision Prevention Trials.

Authors:  Avrum Spira; Matthew B Yurgelun; Ludmil Alexandrov; Anjana Rao; Rafael Bejar; Kornelia Polyak; Marios Giannakis; Ali Shilatifard; Olivera J Finn; Madhav Dhodapkar; Neil E Kay; Esteban Braggio; Eduardo Vilar; Sarah A Mazzilli; Timothy R Rebbeck; Judy E Garber; Victor E Velculescu; Mary L Disis; Douglas C Wallace; Scott M Lippman
Journal:  Cancer Res       Date:  2017-04-01       Impact factor: 13.312

9.  Novel Mutations in MLH1 and MSH2 Genes in Mexican Patients with Lynch Syndrome.

Authors:  Jose Miguel Moreno-Ortiz; María de la Luz Ayala-Madrigal; Jorge Román Corona-Rivera; Manuel Centeno-Flores; Víctor Maciel-Gutiérrez; Ramón Antonio Franco-Topete; Juan Armendáriz-Borunda; Erin Hotchkiss; Lucia Pérez-Carbonell; Jennifer Rhees; Clement Richard Boland; Melva Gutiérrez-Angulo
Journal:  Gastroenterol Res Pract       Date:  2016-05-10       Impact factor: 2.260

10.  Characteristic mutations induced in the small intestine of Msh2-knockout gpt delta mice.

Authors:  Yasunobu Aoki; Mizuki Ohno; Michiyo Matsumoto; Michi Matsumoto; Kenichi Masumura; Takehiko Nohmi; Teruhisa Tsuzuki
Journal:  Genes Environ       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.